PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2025; 14(01): 004-014
DOI: 10.1055/s-0043-1775805
Original Article
Breast Cancer

Usefulness of Indian Diabetes Risk Score in Predicting Treatment-Induced Hyperglycemia in Women Undergoing Adjuvant Chemotherapy for Breast Cancer

Krishna Prasad 
1   Department of Medical Oncology, Mangalore Institute of Oncology, Mangaluru, Karnataka, India
,
Sanath Hegde
2   Department of Radiation Oncology, Mangalore Institute of Oncology, Mangaluru, Karnataka, India
,
Suresh Rao
2   Department of Radiation Oncology, Mangalore Institute of Oncology, Mangaluru, Karnataka, India
,
Rhea Katherine D'souza
3   Department of Research, Research Unit, Mangalore Institute of Oncology, Mangaluru, Karnataka, India
,
Thomas George
3   Department of Research, Research Unit, Mangalore Institute of Oncology, Mangaluru, Karnataka, India
,
Sucharitha Suresh
4   Department of Community Medicine, Father Muller Medical College, Mangalore, Karnataka, India
,
Manjeshwar Shrinath Baliga 
3   Department of Research, Research Unit, Mangalore Institute of Oncology, Mangaluru, Karnataka, India
› Institutsangaben
Funding Mangalore Institute of Oncology funded the study.
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

In the curative treatment of cancer with adjuvant chemotherapy, antineoplastic drugs, along with glucocorticoids, can induce hyperglycemia. The objective of this study was to assess the utility of the Indian Diabetes Risk Score (IDRS) in predicting treatment-induced hyperglycemia in women who were nondiabetic and normoglycemic at the start of chemotherapy. This prospective study was conducted with nondiabetic women who required adjuvant chemotherapy. Participants voluntarily completed the IDRS, providing information on age, waist circumference, family history of diabetes, and physical activity. Chemotherapy-induced hyperglycemia was defined as fasting blood glucose levels ≥100 mg/dL or random blood glucose levels ≥140 mg/dL during treatment. Data were categorized into women who developed hyperglycemia and those who remained normoglycemic during treatment and were analyzed using Fisher's exact test. A significance level of p < 0.05 was applied. Receiver operating characteristic (ROC) curves were constructed to validate the IDRS for predicting hyperglycemia. A total of 208 women met the inclusion criteria and participated in the study. The results revealed that 38.93% (81/208) developed hyperglycemia by the end of chemotherapy, as observed during their first follow-up after treatment. Fisher's exact test demonstrated a significant difference in the total IDRS score and its domains, including family history, physical activity, and waist circumference (p = 0.017–< 0.001), but not age. ROC analysis indicated that an IDRS score above 60 increased the likelihood of developing hyperglycemia, with a sensitivity of 81.3%, specificity of 54.7%, and an area under the curve of 0.727. These findings suggest that the IDRS is a sensitive tool for predicting adjuvant chemotherapy-induced hyperglycemia in breast cancer patients without diabetes. To the best of the authors' knowledge, this is the first study to evaluate the utility of the IDRS in predicting treatment-induced hyperglycemia in women undergoing adjuvant chemotherapy for breast cancer. Ongoing efforts are focused on understanding the underlying mechanisms and strategies for mitigation.

Keywords

Breast Cancer - adjuvant chemotherapy - hyperglycemia - Indian Diabetes Risk Score - diabetes

Informed Consent

Informed consent was obtained from all participants included in the study.


Ethical Approval

This study was performed in accordance with the ethical standards of the institutional and national research committee, the 1964 Declaration of Helsinki and in accordance to the guidelines stipulated by Indian Council of Medical Research 2008 for research after obtaining permission from the hospital ethics committee (MIO/IEC/2018/02/07).




Publikationsverlauf

Artikel online veröffentlicht:
13. Oktober 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India